The radionuclides can be delivered to cancer cells with various types of molecules, e.g. antibodies, antibody fragments and smaller proteins such as affibody molecules and also with peptides.9–12 The application of radionuclide labeled molecules for EGFR- and/or HER2-targeted therapy has so far, to the knowledge of the authors, not been clinically applied for therapy of metastatic urinary bladder cancer. This evidence concerns the gene ERBB2 and urinary bladder cancer.